Pulmatrix (NASDAQ:PULM – Get Free Report) released its quarterly earnings results on Friday. The biotechnology company reported ($0.54) EPS for the quarter, Zacks reports. Pulmatrix had a negative net margin of 96.51% and a negative return on equity of 45.97%.
Pulmatrix Stock Performance
Pulmatrix stock opened at $7.47 on Friday. The stock has a market capitalization of $27.27 million, a P/E ratio of -2.83 and a beta of 1.66. The company’s fifty day moving average price is $7.47 and its 200 day moving average price is $5.19. Pulmatrix has a 1 year low of $1.56 and a 1 year high of $10.40.
Wall Street Analysts Forecast Growth
Separately, StockNews.com initiated coverage on Pulmatrix in a research note on Sunday, January 5th. They issued a “hold” rating for the company.
About Pulmatrix
Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.
Further Reading
- Five stocks we like better than Pulmatrix
- What is a Secondary Public Offering? What Investors Need to Know
- 3 ETFs to Ride the VIX Surge During Market Volatility
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Why Williams-Sonoma Will Hit Fresh Highs in 2025
- What does consumer price index measure?
- Alphabet Stock Becomes a Low-Risk, High-Reward Play
Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.
